Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Receivables (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Change in Receivables for 9 consecutive years, with $5.6 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Receivables rose 826.14% year-over-year to $5.6 million; the TTM value through Mar 2026 reached $12.8 million, up 11832.11%, while the annual FY2025 figure was $6.5 million, 397.92% up from the prior year.
  • Change in Receivables hit $5.6 million in Q1 2026 for Agios Pharmaceuticals, roughly flat from $5.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.6 million in Q1 2026 and bottomed at -$2.7 million in Q2 2022.
  • Average Change in Receivables over 5 years is $948941.2, with a median of $643000.0 recorded in 2024.
  • Year-over-year, Change in Receivables plummeted 218.97% in 2025 and then surged 826.14% in 2026.
  • Agios Pharmaceuticals' Change in Receivables stood at $2.8 million in 2022, then plummeted by 41.85% to $1.6 million in 2023, then plummeted by 39.35% to $991000.0 in 2024, then surged by 459.84% to $5.5 million in 2025, then increased by 0.13% to $5.6 million in 2026.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $5.6 million, $5.5 million, and $43000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.